4basebio PLC (AIM: 4BB), a specialist in synthetic DNA manufacturing and nucleic acids for next-generation therapeutics, announces a significant expansion into a new innovation hub and manufacturing facility in Cambridge, UK, supporting growing demand for research and high-quality grade manufacturing of synthetic DNA for gene and cell therapies, mRNA vaccines, genome editing, or DNA vaccines.

12 MAR 2026

4basebio PLC (AIM: 4BB), a specialist in synthetic DNA manufacturing and nucleic acids for next-generation therapeutics, today announces the appointment of Scott Lorimer as Chief Operating Officer, effective immediately.

3 MAR 2026

4basebio PLC (AIM: 4BB), a specialist in synthetic DNA manufacturing and nucleic acids for next-generation therapeutics, announces the promotion of Christine Wolosin to Chief Commercial Officer. Christine, who joined 4basebio in September 2025 as Vice President, Business Development, will lead the Company's global commercial strategy, business development initiatives, and customer engagement as the Company scales its innovative synthetic DNA platform to serve the rapidly growing cell and gene therapy, mRNA, and vaccine markets.

10 FEB 2026

4basebio PLC (AIM: 4BB), an innovation driven biotechnology company enabling and accelerating development of advanced therapy medicinal products (ATMPs) through its high performant GMP-grade synthetic DNA products, announces that Dr Amy Walker has been appointed as Chief Executive Officer, succeeding Dr Heikki Lanckriet, Founder of the Company.

08 JAN 2026

Press release: 4basebio PLC (AIM: 4BB) announced that it is presenting at Biotech Showcase™ 2026. This year, registered attendees can view 4basebio presentation live. With 24x7 on-demand access, attendees can view recorded presentations at their convenience when scheduling does not allow viewing during the main event week.

27 OCT 2025

Press release: Global pharma partner initiates mRNA therapy trial using 4basebio’s opDNA® template

07 AUG 2025

Press release: A tier one pharmaceutical partner received FDA approval for their IND application for an mRNA vaccine developed using 4basebio’s synthetic DNA

28 JUL 2025

Press release: 4basebio appoints Dr. Manja Boerman to its Board of Directors

07 JUL 2025

Press release: 4basebio plc, ConserV Bioscience Limited, Pegasus Biotech, the University of Leicester, and the National Research Council of Canada (NRC) receive funding to develop and manufacture a broadly protective influenza vaccine